Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lobe Sciences Ltd Ordinary Shares GTSIF

Healthcare Drug Manufacturers - Specialty & Generic
Lobe Sciences Ltd is a technology and services company that provides real estate, financial, management, IP, and branding support for the development of transformational medicine. It is working to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of medications.


OTCPK:GTSIF - Post by User

Lobe Sciences Ltd Ordinary Shares > NEWS: Roadmap for Remainder of 2022 & Early 2023 𓋼𓋺𓋼
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(100)
•••
Comment by GajjarDron Jun 16, 2022 1:50pm
162 Views
Post# 34762000

RE:RE:NEWS: Roadmap for Remainder of 2022 & Early 2023 𓋼𓋺𓋼

RE:RE:NEWS: Roadmap for Remainder of 2022 & Early 2023 𓋼𓋺𓋼
What is most intersting is L-130 drug. As stated in NR... "Lobe will investigate the safety and tolerability of an oral drug candidate, L-130 (a molecular modification of naturally occurring psilocin) and measure absolute pharmacokinetics of this new chemical entity (NCE) given alone and in conjunction with NAC. Following the successful completion of the first-in-man safety trials, a Phase Ib/IIa study will be implemented in healthy volunteers and patients"
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities